About this Research Topic
Anticoagulant therapy has considerably evolved in the last few years, not only because of the availability of novel medications, such as the direct oral anticoagulants, but also because of the development of new clinical and therapeutic indications, which go beyond the classical prevention of cardioembolism in atrial fibrillation and the prevention and treatment of venous thromboembolism. An example of a novel indication is the prevention of new arterial events in subjects with ischemic cardiovascular diseases. If, on one hand, these new agents and indications have extended the use of anticoagulants to an ever-growing number of patients, on the other hand, there has been increasing appreciation that many unmet needs and several grey areas still exist in the field of anticoagulation.
The aim of this Research Topic is to increase our knowledge of the evolving role of anticoagulation in cardiovascular diseases, along with a better understanding of the controversial and unexplored issues that still exist in the arena of anticoagulant therapy.
We welcome original articles, reviews, and opinion papers on the role of anticoagulant therapy in the following areas:
1) Old and new anticoagulants.
2) Old and new indications to anticoagulation in cardiovascular medicine.
3) Anticoagulants for cancer-related thrombosis.
4) Anticoagulants for thrombosis in unusual sites.
5) Anticoagulants in COVID-19 patients and other infectious diseases.
6) Benefits and risks of anticoagulation in special populations (including, but not limited to, severe chronic kidney disease, extreme body weights, and patients with gastrointestinal resections).
7) The role of laboratory tests in guiding the use of direct oral anticoagulants.
8) Anticoagulants and chronic kidney disease.
9) Hemorrhagic stroke risk in traditional and novel anticoagulation.
The aim of this Research Topic is to increase our knowledge of the evolving role of anticoagulation in cardiovascular diseases, along with a better understanding of the controversial and unexplored issues that still exist in the arena of anticoagulant therapy.
We welcome original articles, reviews, and opinion papers on the role of anticoagulant therapy in the following areas:
1) Old and new anticoagulants.
2) Old and new indications to anticoagulation in cardiovascular medicine.
3) Anticoagulants for cancer-related thrombosis.
4) Anticoagulants for thrombosis in unusual sites.
5) Anticoagulants in COVID-19 patients and other infectious diseases.
6) Benefits and risks of anticoagulation in special populations (including, but not limited to, severe chronic kidney disease, extreme body weights, and patients with gastrointestinal resections).
7) The role of laboratory tests in guiding the use of direct oral anticoagulants.
8) Anticoagulants and chronic kidney disease.
9) Hemorrhagic stroke risk in traditional and novel anticoagulation.
Keywords: anticoagulation, heparin, direct oral anticoagulant, vitamin K antagonist, atrial fibrillation, venous thromboembolism, thrombosis, heart valve disease, ischemic cardiovascular disease, secondary cardiovascular prevention, thromboprophylaxis, bleeding, haemorrhage
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
